Umang Swami, Assistant Professor in the Division of Oncology at the Huntsman Cancer Institute, shared on X:
“Real-world mCRPC data (2021–25; n=5,096): marked attrition: only ~53% reach 2L and ~26% 3L. ARPIs dominate early; taxanes later (but only 43% ever receive taxane); Lu-177 uptake rising; Urgent need to optimize treatment and expand access.”
Title: Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
Authors: Gabriel Hooper, Yeonjung Jo, Varun Nandakumar, Georges Gebrael, Zeynep Irem Ozay, Micah Ostrowski, Tanner Hardy, Edwin Lin, Patrick Campbell, Ethan G. Murdock, Laxmi Upadhyay, Krishnam Goel, Vinay Mathew Thomas, Haoran Li, Alexandra O. Sokolova, Umang Swami, Neeraj Agarwal
Other articles featuring Dr. Swami on OncoDaily.
